Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

NCT06924385 | Completed Phase 1

• 1 other identifier: PG-4-1-003
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, single-arm, Phase Ⅰa clinical study designed to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of multiple doses of Telpegfilgrastim Injection in non-pregnant women of childbearing. It contains two cohorts: Cohort 1, healthy childbearing-age non-pregnant participants, and Cohort 2, childbearing-age non-pregnant participants with a history of preeclampsia, totaling 30 non-pregnant women of childbearing age will be enrolled. Each participant in Cohort 2 will go through a screening period, a baseline phase (the day before the first dose), a treatment period, and a follow-up period after dosing.

Conditions

Preeclampsia

Keywords

PEG-rhG-CSF; Telpegfilgrastim Injection

Outcome Measures

Primary Outcomes (20)

• Adverse Event（AE）.

  Week1-6.

• respiration.

  Week1-6.

• body temperature.

  Week1-6.

• Number of participants with clinically significant change from baseline in physical examination.

  Week1-6.

• Number of participants with clinically significant change from baseline in laboratory test.

  Week1-6.

• Electrocardiogram.

  Week1-6.

• Anti-drug antibody.

  week1-6.

• Area under the plasma drug concentration-time curve, AUC 0-t.

  Day36.

• Area Under the Concentration-Time Curve from time 0 to time tau,AUC 0-tau.

  Day36.

• Area under the plasma drug concentration-time curve from time 0 to infinity, AUC 0-∞.

  Day36.

• Maximum concentration (Cmax)

  Day36.

• Time to maximum concentration(Tmax)

  Day36.

• Drug half-life (t1/2)

  Day36.

• Steady-state peak concentration (Css_max)

  Day36.

• Steady-state trough concentration (Css_min)

  Day36.

• Steady-state average concentration (Css_avg)

  Day36.

• Apparent clearance (CL/F)

  Day36.

• Apparent volume of distribution (Vd/F)

  Day36.

• Fluctuation index (DF)

  Day36.

• Accumulation ratio at steady state (Rss)

  Day36.

Secondary Outcomes (8)

• VEGF(Vascular Endothelial Growth Factor)

  Day 36

• IL-4(Interleukin-4)

  Day 36

• IL-6(Interleukin-)

  Day 36

• IL-10(Interleukin-10)

  Day 36

• TNF-α(Tumor Necrosis Factor-α)

  Day 36

Study Arms (5)

Cohort 1:telpegfilgrastim Injection low dose group

EXPERIMENTAL

Drug: Telpegfilgrastim Injection

Cohort 1:telpegfilgrastim Injection middle dose group

EXPERIMENTAL

Drug: Telpegfilgrastim Injection

Cohort 1:telpegfilgrastim Injection high dose group

EXPERIMENTAL

Drug: Telpegfilgrastim Injection

Cohort 2:telpegfilgrastim Injection low dose group

EXPERIMENTAL

Drug: Telpegfilgrastim Injection

Cohort 2:telpegfilgrastim Injection high dose group

EXPERIMENTAL

Drug: Telpegfilgrastim Injection

Interventions

Telpegfilgrastim Injection DRUG

Telpegfilgrastim will be administered as subcutaneous (SC) injection.

Cohort 1:telpegfilgrastim Injection low dose group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants are able to understand and comply with the contents, requirements, and restrictions of the protocol, complete the study as required by the protocol, and are fully aware of the possible adverse reactions, and voluntarily sign the informed consent form before the trial.
• Female, aged between 18 and 45 years old (inclusive of 18 and 45 years old).
• Body Mass Index (BMI) ≥18.5 and \<28.0 kg/m\^2, weight ≥45 kg.
• Healthy, childbearing-age, non-pregnant women: At the screening visit and before the first dose administration, a comprehensive physical examination is conducted, including general physical examination, vital signs (pulse between 50 and 100 bpm at rest, systolic blood pressure between 90 and 139 mmHg, diastolic blood pressure between 50 and 89 mmHg, inclusive of the critical values), as well as laboratory tests \[blood routine, blood biochemistry, coagulation function, thyroid function (FT3, FT4, TSH), urine routine, etc.\] and auxiliary examinations (anteroposterior chest X-ray, 12-lead ECG, ultrasonography) showing all parameters normal or abnormal but without clinical significance.
• Willing to participate in the planned PK blood sampling studies and able to comply with the medication and blood sample collection procedures.
• Negative blood pregnancy test within 24 hours before the first dose administration, and the participant must agree to use effective contraceptive measures during the study period and for 6 months after medication. The participant must agree to use at least one of the following contraceptive methods: condom; subcutaneous contraceptive implant; intrauterine device or intrauterine system; high-efficiency oral contraceptives, with or without progestin; injectable progestin; contraceptive vaginal ring; transdermal contraceptive patch.
• Women of childbearing age with a history of preeclampsia: A documented history of pulmonary embolism (PE), requiring confirmation of the diagnosis through prior hospitalization medical records.

You may not qualify if:

• Healthy, childbearing-age, non-pregnant women: Those with organic lesions in vital organs such as the heart, liver, kidneys, brain, and lungs; a clear history of diseases or other significant conditions affecting the central nervous system, cardiovascular system, cerebrovascular, hematological system, urinary system, digestive system, respiratory system, metabolic and musculoskeletal system; a history of autoimmune diseases; a history of endocrine disorders, such as thyroid dysfunction.
• Healthy, childbearing-age, non-pregnant women: Those with gastrointestinal, liver, kidney, or other known diseases that interfere with drug absorption, distribution, metabolism, or excretion.
• Suffering from malignant tumors or any history of any malignancy within 5 years prior to screening (except for completely resected carcinoma in situ of the cervix, non-metastatic cutaneous squamous cell carcinoma, or basal cell carcinoma).
• History of organ transplantation or use of immunosuppressants agents within in the past 3 months or planned use, including but not limited to; calcineurin inhibitors such as tacrolimus and cyclosporine; mycophenolate agents such as mycophenolate mofetil and mycophenolate sodium enteric-coated tablets; glucocorticoids medications such as prednisone and methylprednisolone; others such as sirolimus, azathioprine, mizoribine and leflunomide;
• A history of poorly controlled psychiatric disorders with medication.
• Current or history of severe or persistent infection within the past 3 months (requiring hospitalization or opportunistic infections); or evidence of active and uncontrolled viral infections, such as HIV, HBV (HBsAg positive), HCV (anti-HCV antibody positive), syphilis, or any bacterial, parasitic, or fungal infection requiring treatment.
• Allergy to rhG-CSF products (including rhG-CSF and PEG-modified rhG-CSF) and their components, or allergy to recombinant human proteins or polypeptide drugs derived from E. coli.
• Use of human granulocyte colony-stimulating factor (G-CSF) therapies within the past 3 months prior to screening; planned or current use of drugs with potential drug interactions with G-CSF therapies, such as lithium;
• Use of any prescription or over-the-counter drugs (including traditional Chinese medicine, health supplements, etc.) within 14 days before the first dose of the test drug or during the drug's 5 half-lives (whichever is longer), unless both the researcher and the sponsor agree that it has no impact on the clinical study.
• Current or planned use of aspirin, statins, and/or any other drugs that affecting the pathogenesis of preeclampsia (including but not limited to low molecular weight heparin, broccoli sprout extract tablets, digoxin immune Fab, recombinant antithrombin III, proton pump inhibitors, metformin, etc.);
• Vaccination with live or attenuated vaccines within 3 months before the start of the trial.
• History of drug abuse, drug use, or alcoholism (drug abuse history or use of narcotics in the past five years; consumption of 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
• Smoking (or use of tobacco products) in the past 3 months, or those who do not agree to refrain from smoking during the study period.
• Participation in a clinical drug trial within 3 months before screening or 5 times the drug's half-life as specified in other trial drug package inserts/investigator brochures/informed consent forms (whichever is longer), or other conditions deemed unsuitable for enrollment by the researcher.
• Women of childbearing age with a history of preeclampsia: A history/current blood system disease (myelodysplastic syndrome, thalassemia, sickle cell anemia, hemolytic anemia, hemophilia, and/or bleeding disorders).

Sponsors & Collaborators

• Peking University Third Hospital: collaborator
• Xiamen Amoytop Biotech Co., Ltd.: lead

Study Sites (1)

Peking University Third Hospital

Beijin, Beijing Municipality, 100191, China

Location

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Study Officials

• Yuan Wei, Ph.D

  Peking University Third Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 3, 2025
• First Posted: April 11, 2025
• Study Start: April 6, 2025
• Primary Completion: January 20, 2026
• Study Completion: January 20, 2026
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)